The TRIUMPH trial found that use of the low-dose fixed-combination triple pill as initial therapy provided better blood pressure control than usual care. In their modelled economic evaluation of TRIUMPH, Thomas Lung and colleagues reported that this triple-pill strategy is cost-effective as a first-line treatment option, especially for older individuals. For their analysis, the authors referred to WHO-CHOICE, which includes health system costs associated with clinic visits, medications, and inpatient hospital admissions, but excludes those associated with laboratory examinations. This is important because the higher-dose triple pill includes 25 mg chlorthalidone, and the following points must be considered.

中文翻译：

---

用6·25 mg氯噻酮优化TRIUMPH。

TRIUMPH试验发现，使用低剂量固定组合三联丸作为初始治疗，与常规治疗相比，可以更好地控制血压。在对TRIUMPH的模型经济评估中，Thomas Lung及其同事报告说，这种三丸策略作为一线治疗方案具有成本效益，特别是对于年长的个体。为了进行分析，作者提到了WHO-CHOICE，其中包括与门诊就诊，药物和住院患者的住院有关的卫生系统费用，但不包括与实验室检查有关的费用。这一点很重要，因为高剂量三联丸包含25毫克的氯噻酮，必须考虑以下几点。